Phase I/II study of docetaxel, CDDP and 5-FU therapy in patients with unresectable or recurrent esophageal cancer (JCOG 0807)

Phase 1

• Conditions: esophageal neoplasm

• Registration Number: JPRN-UMIN000001737
• Lead Sponsor: Japan Clinical Oncology Group (JCOG)

Brief Summary

See the datails via "URL releasing results" above. Also the details can be seen in the JCOG website: http://www.jcog.jp/en/trials/index.html

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-02-27
• Study Completion: 2012-02-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

Not provided

Exclusion Criteria

1) Uncontrollable diabetes mellitus or administration of insulin. 2) Simultaneous or metachronous (within 5 years) double cancers. 3) History of hypersensitivity to DOC, CDDP, 5-FU, or polysorbate 80 4) Active bacterial or fungous infection. 5) Systemic steroids medication 6) Motor paralysis or peripheral neuropathy by any reason 7) Edema by any reason 8) Interstitial pneumonia or fibroid lung 9) Psychosis 10) Pregnant or lactating women

Study & Design

• Study Type: Interventional
• Study Design: Not specified